Patient demographic characteristics at screening (week −4)
| . | EXU . | SC insulin . |
|---|---|---|
| n | 290 | 290 |
| Men/women (%) | 169/121 (58/42) | 161/129 (56/44) |
| Race (%) | ||
| White | 254 (87.6) | 261 (90) |
| Black | 11 (3.8) | 5 (1.7) |
| Asian | 1 (0.3) | 3 (1.0) |
| Hispanic | 19 (6.6) | 18 (6.2) |
| Other | 5 (1.7) | 3 (1.0) |
| Age (years) | 37.6 ± 11.0 | 36.5 ± 11.6 |
| Weight (kg) | 74.8 ± 13.6 | 73.5 ± 13.3 |
| Height (cm) | 172.3 ± 9.7 | 171.2 ± 10.3 |
| BMI (kg/m2) | 25.1 ± 3.0 | 25.0 ± 3.1 |
| A1C (%) | 7.8 ± 1.2 | 7.9 ± 1.2 |
| C-peptide (pmol/ml) | 0.15 ± 0.05 | 0.15 ± 0.05 |
| Duration of diabetes (years) | 18.4 (1.0–51.8) | 17.4 (1.0–48.7) |
| FEV1* | ||
| Observed (l) | 3.50 ± 0.76 | 3.47 ± 0.77 |
| Predicted (%) | 93.1 ± 10.8 | 93.2 ± 10.5 |
| DLCO* | ||
| Observed (ml · min−1 · mmHg−1) | 28.09 ± 6.22 | 27.20 ± 6.41 |
| Predicted (%) | 94.7 ± 13.2 | 92.2 ± 12.6 |
| . | EXU . | SC insulin . |
|---|---|---|
| n | 290 | 290 |
| Men/women (%) | 169/121 (58/42) | 161/129 (56/44) |
| Race (%) | ||
| White | 254 (87.6) | 261 (90) |
| Black | 11 (3.8) | 5 (1.7) |
| Asian | 1 (0.3) | 3 (1.0) |
| Hispanic | 19 (6.6) | 18 (6.2) |
| Other | 5 (1.7) | 3 (1.0) |
| Age (years) | 37.6 ± 11.0 | 36.5 ± 11.6 |
| Weight (kg) | 74.8 ± 13.6 | 73.5 ± 13.3 |
| Height (cm) | 172.3 ± 9.7 | 171.2 ± 10.3 |
| BMI (kg/m2) | 25.1 ± 3.0 | 25.0 ± 3.1 |
| A1C (%) | 7.8 ± 1.2 | 7.9 ± 1.2 |
| C-peptide (pmol/ml) | 0.15 ± 0.05 | 0.15 ± 0.05 |
| Duration of diabetes (years) | 18.4 (1.0–51.8) | 17.4 (1.0–48.7) |
| FEV1* | ||
| Observed (l) | 3.50 ± 0.76 | 3.47 ± 0.77 |
| Predicted (%) | 93.1 ± 10.8 | 93.2 ± 10.5 |
| DLCO* | ||
| Observed (ml · min−1 · mmHg−1) | 28.09 ± 6.22 | 27.20 ± 6.41 |
| Predicted (%) | 94.7 ± 13.2 | 92.2 ± 12.6 |
Data are means ± SD (range) unless otherwise indicated.
FEV1 and DLCO test values at study entry were defined as the means of the values obtained before the first dose of study drug after randomization.